ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

DLBS1442

A development code. Also written as “DLBS1442 100” and “DLBS1442 200”.

Its studies are mostly in Dysmenorrhea · Endometriosis, led by Dexa Medica Group.

Furthest: phase 3, since Sep 10, 20132 company-led studies, 1 open or runningNext primary completion: Dec 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dexa Medica Group21 open or runningphase 3since Sep 10, 2013Sep 10, 2013Dec 2026phase 3 · NCT07937462

Also a collaborator on its studies: PT Equilab International.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 10, 2013First study: phase 3 study in EndometriosisFirst studyNCT01942122 · 60 enrolled · Indonesia
  2. Nov 9, 2026Phase 3 study in DysmenorrheaNCT07937462 · 210 planned · Indonesia

Ahead

  1. Dec 2026Primary completion: phase 3 study in DysmenorrheaNCT07937462

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07937462Dysmenorrhea · Indonesia3RecruitingDec 2026210
NCT01942122Endometriosis · Indonesia3CompletedFeb 202160

How it is read

Names in the registry

  • “DLBS1442”, 1 entry
  • “DLBS1442 100”, 1 entry
  • “DLBS1442 200”, 1 entry

Codes read as this program: DLBS1442.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
DLBS1442 (Dexa Medica Group): development program | ClinicalTrials.gg